LUNG CANCER

In patients with advanced/metastatic non-small cell lung cancer with actionable genomic alterations, datopotamab deruxtecan, an antibody drug conjugate, demonstrated safe antitumor activity.

Can ALK inhibitors have the same impact on other malignancies that harbor ALK rearrangements as is has on non–small cell lung cancer?

Compared indirectly with real-world data of patients treated with standard of care, mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy.

A 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression was seen with brigatinib compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts, leading to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in Japanese patients with non–small cell lung cancer.

Retrospective research suggests a survival benefit with frontline Sequential crizotinib followed by alectinib in ALK-positive non–small cell lung cancer.

The FDA has granted approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer, as detected by an FDA-approved test, and who have received prior platinum-based chemotherapy.

During a Targeted Oncology Case-Based Roundtable event, Hossein Borghaei, DO, MS, moderated a discussion about a 59-year-old man with non–small cell lung cancer.

Findings from the S1619 trial signal that a neoadjuvant triplet is safe and effective for the treatment of resectable mesothelioma.

During a Targeted OncologyTM Case-Based Roundtable event, Dan J. Raz, MD, MAS, and peers discussed the challenges of testing in lung cancer and treatment.

Data from an exploratory analysis of the phase 3 IMpower010 trial show the disease-free survival benefit of adjuvant atezolizumab in the treatment of early-stage non–small cell lung cancer.

The first patient has been dosed in the phase 1b/2 trial of ERAS-007, an extracellular signal-regulated kinase inhibitor, for the treatment of advanced non-small cell lung cancer.

The addition of ramucirumab to gemcitabine in the second-line setting led a survival advantage for patients malignant pleura mesothelioma.

During separate virtual live events, David R. Gandara, MD, and Alexander Spira, MD, PhD, discussed the timing of durvalumab in non–small cell lung cancer from the PACIFIC trial with participating physicians.

An otherwise healthy 60-year-old woman, who has quit smoking for 8 years after 13 pack years, presented with a nonproductive cough. The patient was diagnosed with non–small cell lung cancer. Oncologists discuss the scenario during a Case-Based Roundtable event.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, provide an overview of their major conclusions and clinical pearls for the treatment approach of EGFR Exon 20 Insertion+ NSCLC.

Experts review the toxicity of mobocertinib and further discuss the key findings from the EXCLAIM Trial.

The high prevalence of bone metastases in non–small cell lung cancer led 2 institutions to investigate how these metastases impact survival in patients treated with immune checkpoint inhibitors.

A 59-year-old White male presented with chest pain, cough, and dyspnea and an image-guided biopsy revealed poorly differentiated adenocarcinoma of the lung.

In an interview with Targeted Oncology™, Eric S. Nadler, MD, discusses IMpower133’s real-world implication and the effects immunotherapy has had on the ES-SCLC space.

A new cell therapy containing autologous tumor-infiltrating lymphocytes followed by nivolumab maintenance is both safe and clinically active in patients with metastatic non-small cell lung cancer.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, review amivantamab and poziotinib as other treatment options for EGFR Exon 20 Insertion+ NSCLC.

An explanation of the EXCLAIM Trial and the mechanism of action, clinical development, and the overall clinical development program of mobocertinib.

Jared Weiss, MD, led a discussion about a 59-year-old patient with RET-fusion-positive non–small cell lung cancer during a Targeted Oncology Case-Based Roundtable event.

Treatment with amivantamab-vmjw in the phase 1 CHRYSALIS study has released anti-tumor activity in patients with non-small cell lung cancer harboring MET exon 14 skipping mutations treated with the agent.